1. Scrip
  2. >>Business

One Plus One Equals Three For Calluna

 
• By Elizabeth Cairns

Two early-stage companies have merged to form Calluna Therapeutics, which is targeting immunological diseases and hopes to get to proof of concept by mid-2026.

Merger
• Source: Shutterstock

Merging two companies and securing a €75m ($81m) series A venture round is not an unimpressive achievement, particularly when the combined group is yet to achieve proof of concept, and is active in the tricky and competitive arena of immunology. But Calluna Pharma emerged last week in just this manner, and has given itself three years to prove its pipeline’s value.

Key Takaways
  • Oxitope Pharma and Arxx Therapeutics have merged to form Calluna Pharma

Calluna does have a bit of a leg-up in that its CEO John Montana, is, in addition to his duties...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

 
• By Mandy Jackson

MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.

Pfizer Jumps Back Into Obesity With $4.9bn Bid For Metsera

 
• By Joseph Haas

Months after terminating obesity candidate danuglipron, Pfizer is placing a hefty bet on Metsera and what it calls its highly differentiated incretin/amylin analog candidates.

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

More from Scrip

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.